Company overview
MIP Diagnostics Limited develops and manufactures nanoMIPs, linear MIPs, bulk MIP and Rationally Designed Polymers using its proprietary processes.
Molecularly Imprinted Polymers (MIPs) are ‘synthetic’ affinity reagents and the nanoMIP format provides a more robust alternative to antibodies, typically with similar or greater affinity coupled with additional unique characteristics.
Company information
Head office
- Bedfordshire
CEO
- Stephane Argivier
Chair
- Jim Reid
BGF office
BGF team
Investment date
- Jul 2020
Total BGF investment
- £2 million
